Gilead Sciences

This is an early-stage study to test the safety and side effects of a new drug called zamzetoclax (GS-9716) in people with advanced solid cancers. The drug is being tested both by itself and in combination with other approved cancer therapies. The main goal is to find a safe dose…

This large, late-stage study is comparing a new two-drug combination plus chemotherapy against the current standard treatment for people with newly diagnosed, advanced non-small cell lung cancer that has spread. The main goal is to see if the new combination helps patients live l…

This study is testing the safety and correct dosing of several HIV medications in children and teenagers (from 4 weeks to under 18 years old) who already have their HIV under control with treatment. The goal is to see how the drugs work in younger bodies and to monitor for any si…

This study is testing whether switching to a new two-drug combination (bictegravir plus lenacapavir) works as well as a person's current complex HIV medication regimen. It involves nearly 700 people whose HIV is already well-controlled. The main goal is to see if the new combinat…

This study is testing whether a new combination of two experimental drugs, taken just once a week by mouth, is as safe and effective as the current standard daily pill (Biktarvy) for treating HIV. It will involve 675 adults who are starting HIV treatment for the first time. The m…

This study is testing a single, once-daily pill containing three HIV medicines in children and adolescents. The main goals are to understand how the drug works in younger bodies, confirm the right dose, and check its safety and effectiveness at keeping the virus under control. It…

This study is testing a new weekly pill combination (islatravir + lenacapavir) for people with HIV whose virus is already well-controlled on daily medication. The main goal is to see if the weekly pills are as effective at keeping the virus suppressed after 24 weeks. It involves …

This large, late-stage study is testing whether a newer targeted drug called sacituzumab govitecan works better than standard chemotherapy options for people with advanced endometrial (uterine) cancer. It is for patients whose cancer has grown or returned after receiving platinum…

This early-stage study aims to check the safety and how the body processes a new experimental drug called GS-0272 in people with rheumatoid arthritis. It will involve about 55 adults who have the condition and are taking certain standard medications. The main goal is to see how w…

This study is testing if switching to a new two-drug combination pill (bictegravir/lenacapavir) works as well as staying on the current three-drug standard pill (Biktarvy) for people whose HIV is already well-controlled. It involves about 577 adults who are currently stable on th…

This study is testing if adding a second immunotherapy drug (domvanalimab) to a standard treatment (zimberelimab plus chemotherapy) works better for people with advanced head and neck cancer that has returned or spread. It will involve about 100 participants who have not yet rece…

This study is testing several different combinations of immunotherapy drugs for people with advanced non-small cell lung cancer that has spread. The main goals are to see if these combinations can shrink tumors and to check how safe they are for patients. It will involve about 40…

This study is testing a new long-acting HIV drug called lenacapavir for people whose current medications are failing due to drug resistance. It involves about 72 adults and adolescents whose HIV is resistant to most available drug classes. The goal is to see if adding this new dr…

This study is testing how well a drug called sacituzumab govitecan works for Chinese patients with advanced triple-negative breast cancer that has continued to grow despite at least two prior chemotherapy treatments. The main goal is to see how many patients' tumors shrink in res…

This study is testing if a new drug combination works better than current standard treatments for people with a hard-to-treat type of advanced breast cancer. It involves 443 adults with triple-negative breast cancer that has spread and who have not yet received treatment for thei…

This study is following 500 people with primary biliary cholangitis (PBC), a chronic liver disease, to see how safe and effective the drug seladelpar is over a long period. The main goal is to check for side effects, but researchers will also see if the drug helps control the dis…

This is the first human study of an experimental cancer drug called GS-9911. Researchers are testing its safety and finding the right dose when given alone or combined with an immunotherapy drug. The study includes 45 adults with advanced solid tumors who have run out of standard…

This is an early-stage study to find a safe dose of a new drug called GS-4528 for people with advanced solid tumors. Researchers will test the drug by itself and combined with an existing immunotherapy. The main goal is to understand the side effects and determine the best dose f…

This study is testing whether a newer targeted drug called sacituzumab govitecan works better than standard chemotherapy options for people with a common type of advanced breast cancer that has stopped responding to hormone therapy. It involves 654 adults whose cancer has spread …

This study is testing an investigational drug called GS-1427 to see if it can help control the symptoms of moderate to severe ulcerative colitis. It will involve 228 adults whose current treatments aren't working well enough. Participants will receive either the drug or a placebo…

This study is testing whether the drug sacituzumab govitecan can help control advanced solid tumors that have grown despite standard chemotherapy. It is enrolling 53 adults with specific types of cancer, including some stomach, esophageal, cervical, lung, and bile duct cancers, t…

This study compares an experimental drug called sacituzumab govitecan against standard chemotherapy options for Asian patients with advanced breast cancer that has spread and stopped responding to at least two prior chemotherapy treatments. The trial aims to see if the new drug c…

This study is testing a new combination of cancer drugs for people with advanced non-small cell lung cancer that has spread and lacks certain genetic targets. It aims to see if adding the drug sacituzumab govitecan to standard treatments (pembrolizumab with or without chemotherap…

This study is testing whether a newer drug called sacituzumab govitecan works better than standard chemotherapy for people with advanced triple-negative breast cancer. It's for patients whose cancer has spread and either doesn't respond to certain immunotherapies or who have alre…

This study collects long-term safety and effectiveness data from people with chronic hepatitis D who are being treated with bulevirtide. It follows 170 participants who are either already receiving the medication or are scheduled to start treatment. The main goal is to monitor li…

This study is testing if switching to a new weekly pill (islatravir/lenacapavir) works as well as continuing the current daily medication for people whose HIV is already well-controlled. It will involve about 600 people who have had undetectable virus levels for at least six mont…

This study is testing whether a new combination of two experimental drugs, taken just once a week, is as safe and effective as the current standard daily pill for managing HIV. It involves about 675 adults whose HIV is already well-controlled with daily medication. The goal is to…

This study is testing if people with well-controlled HIV can safely switch from taking daily medication to a new weekly pill. It will compare the weekly pill (islatravir/lenacapavir) to continuing their current standard treatment. The main goal is to see if the weekly pill keeps …

This study tested an experimental drug called sacituzumab govitecan in people with advanced solid tumors that had spread and stopped responding to standard treatments. The drug is designed to deliver chemotherapy directly to cancer cells. Researchers measured how well the tumors …

This study is testing if the antiviral medicine tenofovir is safe and effective at controlling chronic hepatitis B in children aged 2 to under 12. About 90 children will be randomly assigned to receive either the real medicine or a placebo (a dummy pill) for 48 weeks. The main go…

This study is testing a new, long-acting injection called lenacapavir, given just twice a year, to see if it can safely prevent HIV infection in women in the United States. It will compare this injection to a standard daily pill. The main goals are to see how the drug moves throu…

This large study tested whether a daily pill containing two drugs (F/TAF) is safe and effective at preventing HIV infection. It involved over 5,300 men and transgender women who have sex with men and are at high risk of getting HIV. The study compared this new pill to an older, s…

This study aimed to test if a drug called obeldesivir could safely prevent Ebola or Marburg virus disease in people who had recently been exposed to these viruses. It was designed for people who had high-risk contact with an infected person or their bodily fluids. The trial was w…

This study is testing a new, long-acting injection called lenacapavir, given just twice a year, to see if it can safely prevent HIV infection. It involves 181 adults in the U.S. who inject drugs and are at high risk for HIV. The main goals are to see how the drug moves through th…

This large Phase 3 study is testing whether a new drug called lenacapavir, given as an injection just twice a year, can safely prevent HIV infection. It enrolled over 3,200 cisgender men, transgender women, transgender men, and nonbinary people aged 16+ who have condomless sex wi…

This study is testing a new long-acting injection called lenacapavir for preventing HIV. It compares how well people stick with getting the shot twice a year versus taking a daily pill. The research will also look at the safety of both methods, how acceptable they are to particip…